Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause C-reactive protein abnormal? 3,259 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,259 reports of C-reactive protein abnormal have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 3.3% of all adverse event reports for TOCILIZUMAB.

3,259
Reports of C-reactive protein abnormal with TOCILIZUMAB
3.3%
of all TOCILIZUMAB reports
1,206
Deaths
2,099
Hospitalizations

How Dangerous Is C-reactive protein abnormal From TOCILIZUMAB?

Of the 3,259 reports, 1,206 (37.0%) resulted in death, 2,099 (64.4%) required hospitalization, and 1,321 (40.5%) were considered life-threatening.

Is C-reactive protein abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 3,259 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause C-reactive protein abnormal?

METHOTREXATE (3,734) ADALIMUMAB (3,629) ETANERCEPT (3,592) ABATACEPT (3,402) LEFLUNOMIDE (3,279) HYDROXYCHLOROQUINE (3,245) SULFASALAZINE (2,823) INFLIXIMAB (2,676) RITUXIMAB (2,608) TOFACITINIB (2,062)

Which TOCILIZUMAB Alternatives Have Lower C-reactive protein abnormal Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All C-reactive protein abnormal Reports All Drugs Causing C-reactive protein abnormal TOCILIZUMAB Demographics